• A Straube, C Gaul, S Förderreuther, P Kropp, M Marziniak, S Evers, W H Jost, H Göbel, C Lampl, P S Sándor, A R Gantenbein, H-C Diener, German Migraine and Headache Society, German Society for Neurology, Austrian Headache Society, and Swiss Headache Society.
• Neurologische Klinik, Universität München und Oberbayerisches Kopfschmerzzentrum, Marchioninistr. 15, 81377 München, Deutschland. astraube@nefo.med.uni-muenchen.de
• Nervenarzt. 2012 Dec 1; 83 (12): 1600-8.

AbstractChronic migraine (CM) was first defined in the second edition of the International Headache Society (IHS) classification in 2004. The definition currently used (IHS 2006) requires the patient to have headache on more than 15 days/month for longer than 3 months and a migraine headache on at least 8 of these monthly headache days and that there is no medication overuse. In daily practice the majority of the patients with CM also report medication overuse but it is difficult to determine whether the use is the cause or the consequence of CM. Most the patients also have other comorbidities, such as depression, anxiety and chronic pain at other locations. Therapy has to take this complexity into consideration and is generally multimodal with behavioral therapy, aerobic training and pharmacotherapy. The use of analgesics should be limited to fewer than 15 days per month and use of triptans to fewer than 10 days per month. Drug treatment should be started with topiramate, the drug with the best scientific evidence. If there is no benefit, onabotulinum toxin A (155-195 Units) should be used. There is also some limited evidence that valproic acid and amitriptyline might be beneficial. Neuromodulation by stimulation of the greater occipital nerve or vagal nerve is being tested in studies and is so far an experimental procedure only.

10 keywords...

hide…